of brain dystrophin expression will likely require other methods (20) (21) (22) (23) . We also harvested sperm from AAV-injected male mdx mice and tested gene editing by T7E1 assay. No cleavage bands were detected (fig. S13D) ; however, more sensitive methods such as deep sequencing might be required to evaluate the risk of unexpected germline editing. Additionally, AAV vectors with tissuespecific promoters should enhance the safety of systemic gene editing.
Our results show that AAV-mediated Myoediting can rescue the reading frame and expression of dystrophin in postnatal mdx mice. The efficiency of restoration of dystrophin-positive myofibers increases with time, likely reflecting persistent expression of gene-editing components. Exon skipping by NHEJ-mediated genomic editing allows for the permanent removal of the disease-causing mutation and was about 10 times as efficient as gene correction by HDR (7) . Myoediting by NHEJ does not require precise genetic modification. Instead, any types of indels that disrupt either a splice donor or acceptor sequence in a mutant exon result in exon skipping. It is noteworthy that the consensus sequence for splice acceptors is NAG, corresponding to the PAM sequence for Cas9 from S. pyogenes (NGG or NAG), so any exon can potentially be skipped by this approach.
It has been estimated that even low-level expression of dystrophin (4 to 15%) can partially ameliorate cardiomyopathy (24) and protect against eccentric contraction-induced injury in skeletal muscle (25) . The efficiency of restoration of dystrophin expression observed after delivery of Myoediting components to mdx mice by AAV is therefore within the range expected to provide therapeutic benefit.
Off-target effects are a safety concern in the eventual translation of gene-editing methods to humans. We did not observe off-target mutations at 10 potential off-target sites in the mouse genome nor any abnormalities in mice after AAV9 delivery of Myoediting components. However, off-target mutations may occur at sites beyond those predicted in silico; hence, a comprehensive and unbiased analysis, such as whole-genome sequencing, would be an essential component of future efforts to establish the safety of this approach (26) (27) (28) . Given that Myoediting offers the potential for durable and progressive therapeutic response in postmitotic adult tissue, we propose that this methodology may warrant investigation as a way to restore muscle function in DMD patients, alone or in combination with other therapies (3, 29 
D
uchenne muscular dystrophy (DMD) is among the most prevalent fatal genetic diseases, occurring in 1 out of 5000 male births (1). It results in muscle degeneration, loss of mobility, and premature fatality. DMD mutations are often deletions of one or more exons in the dystrophin gene that disrupt the reading frame of the gene and lead to a complete loss of functional dystrophin expression (2) . In contrast, Becker muscular dystrophy (BMD) is associated with much milder symptoms relative to DMD and is caused by internal, in-frame deletions of the dystrophin gene, resulting in expression of a truncated but partially functional dystrophin protein (3). Because of the genetic nature of the disease, gene therapy is a promising option to treat DMD. However, the very large size of the dystrophin cDNA presents a challenge to gene delivery. Consequently, some therapeutic strategies aim to generate a BMDlike dystrophin. These approaches include the development of mini/micro-dystrophin genes for delivery by adeno-associated virus (AAV) vectors (4-7) and oligonucleotide-mediated exonskipping therapies designed to restore the reading frame of the transcript (8, 9) . For example, removal of exon 51 can address 13% of DMD patient mutations, and exon-skipping strategies could be extended to other regions of the gene to collectively treat 83% of DMD patients (10). In SCIENCE sciencemag.org contrast, genome editing technologies can be used to directly correct disease-causing genetic mutations (11) and may be a preferred approach for a single treatment to restore stable expression of a dystrophin protein that contains most of the normal structure and function and is also under physiologic control of the natural promoter. In particular, the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 genome editing system, which uses the Cas9 nuclease to cleave DNA sequences targeted by a single guide RNA (gRNA) (12) , has recently created new possibilities for gene therapy by making precise genome modifications possible in cultured cells (13) (14) (15) (16) and in animal studies (17) (18) (19) (20) . Analogous to exon-skipping therapies, CRISPRmediated removal of one or more exons from the genomic DNA could be applied to the treatment of 83% of DMD patients. Moreover, this approach can be readily extended to targeting multiple exons within mutational hotspots, such as the deletion of exons 45 to 55 that could address 62% of DMD patients with a single-gene editing strategy (21) . We and others have applied these tools to correct dystrophin mutations in cultured human cells from DMD patients (21) (22) (23) (24) (25) (26) and in mdx mouse embryos (27) . A critical remaining challenge is to translate these proof-ofprinciple results into a clinically relevant approach for genome editing in muscle tissue in vivo (28) . The use of genome editing for exon removal, rather than replacing missing exons to restore a full-length gene, may be desirable for several reasons. Editing by exon removal takes advantage of the relatively efficient nonhomologous end joining pathway that is active in all cell types, in contrast to targeted gene addition by the homology-directed repair pathway that is down-regulated in postmitotic cells such as skeletal myocytes and myofibers. This method also avoids the need to deliver a DNA repair template. Finally, gene editing to delete exons will be more applicable to large patient populations that include a variety of mutations, in contrast to patient-specific editing strategies that restore unique gene deletions.
The mdx mouse model of DMD has a nonsense mutation in exon 23, which prematurely terminates protein production (29) . Removal of exon 23 from the transcript through oligonucleotidemediated exon skipping restores functional dystrophin expression and improves muscle contractility (30, 31) . Here, we have developed an AAV-based strategy for the treatment of DMD in the mdx mouse by harnessing the unique multiplexing capacity of CRISPR-Cas9 to excise exon 23 from the dystrophin gene. We hypothesized that CRISPR-mediated removal of exon 23 from the genomic DNA would restore dystrophin expression and improve muscle function (Fig. 1A) .
We used AAV serotype 8 (AAV8) as a vector for delivery and expression of the components of the CRISPR-Cas9 system to skeletal and cardiac muscle (32) (C) H&E staining shows no obvious adverse response to the AAV-Cas9 treatment. Additionally, there is reduced area of necrotic fibers. Scale bars: 600 mm (full-view images); 100 mm (high-power images). For panels A to C, asterisk marks the same area in serial sections. (D) Significant improvement in specific twitch force (Pt) and tetanic force (Po), as measured by an in situ contractility assay in Cas9-gRNA-treated muscles. Treated muscles also showed significantly better resistance to damage caused by repeated cycles of eccentric contraction (n = 7 muscles, mean + SEM). Overall treatment effect by analysis of variance (P < 0.05). Asterisk, significantly different from the sham group (P < 0.05).
Fig. 2. In vivo genome editing restores dystrophin protein expression. (A) Western blot for dystrophin shows recovery of dystrophin expression (+, AAV-injected muscle; -, contralateral muscle).
Comparison to protein from wild-type (WT) mice indicates restored dystrophin is~8% of normal amounts (n = 6 muscles, mean + SEM). (B) Dystrophin immunofluorescence staining shows abundant (67%) dystrophin-positive fibers in Cas9-gRNAtreated groups (scale bar, 100 mm; n = 7 muscles, mean + SEM). Asterisk, significantly different from the sham group (P < 0.05).
described for in vivo genome editing applications (20) . A second AAV vector with two gRNA expression cassettes was also produced to express gRNAs targeted to introns 22 and 23. We expected that simultaneous DNA cleavage in both introns by Cas9-gRNA complexes would remove exon 23 from the genome and result in production of an internally truncated, but highly functional, dystrophin protein. A panel of gRNAs was designed by manual inspection for the SaCas9 protospacer adjacent motif (PAM) (5′-NNGRRT-3′) with close proximity to exon 23 and prioritized according to predicted specificity by minimizing potential offtarget sites in the mouse genome. The best set of gRNAs was then selected on the basis of in vitro gene editing efficiency (fig. S1 ).
The Cas9 and gRNA AAV vectors were premixed in equal amounts and injected into the tibialis anterior muscle of mdx mice. Contralateral limbs received saline injection. At 8 weeks after injection, the muscles were harvested and analyzed for deletion of exon 23 from the genomic DNA and mRNA, and expression of dystrophin protein. End-point polymerase chain reaction (PCR) across the genomic locus revealed the expected~1171-base pair (bp) deletion in all injected limbs (Fig. 1B) . Droplet digital PCR (ddPCR) was used to quantify the percentage of modified alleles by separately amplifying the unmodified or deleted DNA templates. ddPCR showed that exon 23 was deleted in~2% of all alleles from the whole-muscle lysate (Fig. 1C) . Sanger sequencing of gel-extracted bands confirmed the deletion of exon 23 as predicted, without any additional insertions or deletions (indels) (Fig. 1B) . Deep sequencing of these amplicons indicated a strong preference (~66%) for precise ligation of cut products ( fig. S2) . Regardless, the distribution of indels in the deletion should not affect transcript production, as the indels occur in the intronic region. Deep sequencing of gRNA target sites and the top 10 predicted off-target sites for each gRNA indicated~3% indel formation at the target sites and low (~1%, gRNA1-OT8) or undetectable offtarget gene editing at the predicted off-target sites (tables S2 and S3 and fig. S3 ).
Reverse transcriptase (RT)-PCR of mRNA extracted from muscle lysates showed a fraction of transcripts without exon 23 (Fig. 1D) . Quantitative ddPCR of the cDNA also showed significant editing of the mRNA transcript, with exon 23 excluded in 59% of transcripts (Fig. 1E) . The high frequency of mRNA modification is likely due to protection of the D23 transcripts from nonsensemediated decay. This is supported by an increase in total dystrophin mRNA from 5% of wild-type mRNA levels in nontreated muscles to 12% in Cas9-gRNA-treated muscles ( fig. S4) .
Western blot of whole-muscle lysates showed substantial recovery of dystrophin protein to~8% of wild-type levels ( Fig. 2A) . By immunostaining, 67% of myofibers expressed dystrophin (Figs. 2B and 3A). Immunofluorescence staining also confirmed Cas9 expression in myonuclei ( fig. S5) . Collectively, the molecular analyses of genomic deletion, exon removal from the transcript, and abundant protein expression validated CRISPRmediated restoration of a near-full-length dystrophin protein to amounts above the established benchmarks for functional recovery and therapeutic benefit. In particular, it is reported that as little as 4% of normal dystrophin expression level is sufficient to improve muscle function (33, 34) , and human natural history studies show that 30% protein expression may be sufficient for a completely asymptomatic phenotype (35) . Therefore, we evaluated therapeutic benefit in CRISPRtreated mdx mice. We first examined sarcolemmal neuronal nitric oxide synthase (nNOS) localization. nNOS is absent in the sarcolemma of the mdx mouse and DMD patients, owing to the loss of the nNOS-binding site in spectrin repeats 16 and 17 in the dystrophin protein (36, 37) . The mislocalization of nNOS contributes to DMD pathogenesis (36, 37) . In CRISPR-treated muscles, nNOS activity was restored at the sarcolemma, closely mirroring dystrophin staining in serial sections (Fig. 3, A and B) and resembling that of wild-type muscle ( fig. S6 ).
Dystrophin assembles a series of transmembrane and cytosolic proteins into the dystrophinassociated glycoprotein complex (DGC) to link the cytoskeleton and the extracellular matrix (1). In mdx mice and DMD patients, these proteins are mislocalized. Immunostaining of serial muscle sections showed recovery of DGC proteins in Cas9-gRNA-treated muscles, but not the contralateral controls (figs. S7 to S9). Histological examination showed improved overall morphology of CRISPR-Cas9-treated muscles (Fig. 3C and fig.  S10 ). The number of infiltrating macrophages and neutrophils was substantially decreased in treated muscle, indicating a reduction of the inflammation typical of dystrophic muscle (fig. S11). Hematoxylin and eosin (H&E) staining of serial sections showed no obvious toxicity in response to the vector or transgene in this study (Fig. 3C) . However, potential immune responses to the AAV capsid, Cas9, and dystrophin are important subjects for future studies (7, (38) (39) (40) .
Next, we assessed muscle function. The specific twitch (Pt) and tetanic (Po) force were significantly improved in Cas9-gRNA-treated muscle (*P < 0.05, Fig. 3D ). Treated muscles showed significantly improved resistance to eccentric contraction injury, maintaining 50% of the initial force relative to 37% in untreated muscle (*P < 0.05 at marked cycles, Fig. 3D ). Further, pathologic hypertrophy was mitigated in Cas9-gRNAtreated muscle (table S4) . Collectively, these results show that CRISPR-Cas9-mediated dystrophin restoration improved muscle structure and function.
To assess the effects of dystrophin restoration early in life, we performed intraperitoneal injections of the AAV vector into postnatal day 2 (P2) neonatal mice. This led to recovered dystrophin expression in abdominal muscles, diaphragm, and heart at 7 weeks after injection (figs. S12 and S13). Notably, these muscles are responsible for cardiac and pulmonary health, which are severely weakened and responsible for the premature death of DMD patients. Finally, intravenous administration of AAV vectors in 6-week-old adult mdx showed substantial recovery of dystrophin in the cardiac muscle (Fig. 4) . Efficient correction in cardiac tissues will be an important end-point to prevent premature death of DMD patients.
In this study, we have demonstrated the therapeutic benefit of AAV-mediated CRISPR-Cas9 genome editing in an adult mouse model of DMD. Our results include correction in a single muscle following local delivery and in the heart following intravenous delivery to neonatal and adult mice. As systemic delivery of AAV vectors to skeletal and cardiac tissue is well established, we expect this approach to confer body-wide therapeutic benefits. The accompanying articles from Wagers and colleagues (41) and Olson and colleagues (42) adopt a similar approach to CRISPR-Cas9-based correction of dystrophic mice using delivery with AAV9, demonstrating generality across muscle-tropic AAV serotypes. Moreover, the Wagers group's demonstration of efficient editing of Pax7-positive muscle satellite cells (41) suggests that gene correction may improve as the mature muscle fibers are populated with the progeny of these progenitor cells, as was observed in mosaic mice generated by CRISPR-Cas9 delivery to single-cell zygotes (27) . Indeed, we have observed that dystrophin restoration by genome editing is maintained for at least 6 months after treatment ( fig. S14 ).
Continued optimization of vector design will be important for potential clinical translation of this approach, including evaluation of various AAV capsids and tissue-specific promoters. Additionally, although dual-vector administration has been effective in body-wide correction of animal models of DMD (43) , optimization to engineer a single-vector approach may increase efficacy and translatability. These three studies (41, 42) establish a strategy for gene correction by a singlegene editing treatment that has the potential to achieve effects similar to those seen with weekly administration of exon-skipping therapies (8, 9, 30, 31) . More broadly, this work establishes CRISPR-Cas9-mediated genome editing as an effective tool for gene modification in skeletal and cardiac muscle and as a therapeutic approach to correct protein deficiencies in neuromuscular disorders and potentially many other diseases. The continued development of this technology to characterize and enhance the safety and efficacy of gene editing will help to realize its promise for treating genetic disease.
